Consort Medical plc (LON:CSRT) has earned an average rating of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is GBX 1,200.80 ($16.28).
A number of research analysts have issued reports on the company. Stifel Nicolaus restated a “buy” rating and issued a GBX 1,250 ($16.95) price objective on shares of Consort Medical in a research note on Thursday, November 9th. N+1 Singer downgraded Consort Medical to a “hold” rating in a research note on Tuesday, December 5th. Shore Capital restated a “buy” rating on shares of Consort Medical in a research note on Tuesday, December 5th. Finally, Numis Securities upped their price objective on Consort Medical from GBX 1,084 ($14.70) to GBX 1,144 ($15.51) and gave the company a “hold” rating in a research note on Wednesday, December 6th.
Consort Medical (CSRT) opened at GBX 1,150 ($15.60) on Tuesday. The firm has a market cap of $569.71 and a price-to-earnings ratio of 2,875.00. Consort Medical has a fifty-two week low of GBX 965 ($13.09) and a fifty-two week high of GBX 1,224 ($16.60).
Consort Medical Company Profile
Consort Medical PLC is a contract development and manufacturing organization (CDMO). The Company’s principal activities include designing, development and manufacture of medical drug delivery devices and services for the pharmaceutical industry. The Company operates through two segments: Bespak and Aesica.
Receive News & Ratings for Consort Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Consort Medical and related companies with MarketBeat.com's FREE daily email newsletter.